Literature DB >> 1911210

Systemic immunotoxin therapy of cancer: advances and prospects.

E J Wawrzynczak1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1911210      PMCID： PMC1977692          DOI： 10.1038/bjc.1991.374

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  55 in total

1.  A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin.

Authors:  V K Chaudhary; M G Gallo; D J FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

2.  Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin.

Authors:  E J Wawrzynczak; A J Cumber; R V Henry; J May; D R Newell; G D Parnell; N R Worrell; J A Forrester
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

3.  Strategies in antibody therapy of cancer.

Authors:  E J Wawrzynczak; A J Davies
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

4.  Biochemical, cytotoxic and pharmacokinetic properties of an immunotoxin composed of a mouse monoclonal antibody Fib75 and the ribosome-inactivating protein alpha-sarcin from Aspergillus giganteus.

Authors:  E J Wawrzynczak; R V Henry; A J Cumber; G D Parnell; E J Derbyshire; N Ulbrich
Journal:  Eur J Biochem       Date:  1991-02-26

5.  Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a proteolytically-cleavable spacer sequence.

Authors:  M O'Hare; A N Brown; K Hussain; A Gebhardt; G Watson; L M Roberts; E S Vitetta; P E Thorpe; J M Lord
Journal:  FEBS Lett       Date:  1990-10-29       Impact factor: 4.124

6.  Comparative biochemical, cytotoxic and pharmacokinetic properties of immunotoxins made with native ricin A chain, ricin A1 chain and recombinant ricin A chain.

Authors:  E J Wawrzynczak; A J Cumber; R V Henry; G D Parnell
Journal:  Int J Cancer       Date:  1991-01-02       Impact factor: 7.396

7.  Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin.

Authors:  E J Wawrzynczak; G J Watson; A J Cumber; R V Henry; G D Parnell; E P Rieber; P E Thorpe
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

8.  Covalent binding of human alpha 2-macroglobulin to deglycosylated ricin A chain and its immunotoxins.

Authors:  M A Ghetie; J W Uhr; E S Vitetta
Journal:  Cancer Res       Date:  1991-03-01       Impact factor: 12.701

9.  The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides.

Authors:  J M Lambert; G McIntyre; M N Gauthier; D Zullo; V Rao; R M Steeves; V S Goldmacher; W A Blättler
Journal:  Biochemistry       Date:  1991-04-02       Impact factor: 3.162

10.  Preclinical assessments of 90Y-labeled C110 anti-carcinoembryonic antigen immunotoxin: a therapeutic immunoconjugate for human colon cancer.

Authors:  T Ito; H Qiu; J A Collins; A B Brill; D K Johnson; T W Griffin
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701
View more
  17 in total

Review 1.  Targeted kill: from umbrellas to monoclonal antibodies.

Authors:  V S Byers; R W Baldwin
Journal:  J Clin Immunol       Date:  1992-11       Impact factor: 8.317

Review 2.  Immunotoxins to human small-cell lung cancer.

Authors:  E J Wawrzynczak; E J Derbyshire
Journal:  Cell Biophys       Date:  1992 Aug-Dec

3.  Cytotoxic properties of a ricin A chain immunotoxin recognising the cluster-5A antigen associated with human small-cell lung cancer.

Authors:  E J Derbyshire; R A Stahel; E J Wawrzynczak
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 4.  A role for gamma scintigraphy in cancer immunology and immunotherapy.

Authors:  A C Perkins; M V Pimm
Journal:  Eur J Nucl Med       Date:  1992

5.  Different cytotoxic activity and intracellular fate of an anti-CD5-momordin immunotoxin in normal compared to tumour cells.

Authors:  G Porro; P Lento; F Marcucci; G Gromo; D Modena
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

6.  Requirement of monocytes and T-helper cells during development of tumor cell cytotoxicity in targeted T cells.

Authors:  K A Smans; M F Hoylaerts; M E De Broe
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

7.  Distribution of radiolabelled anti-CA125 monoclonal antibody OC125-F(ab)2-fragment following resection guided by antibodies (REGAJ) in ovarian cancer patients.

Authors:  M M Uttenreuther-Fischer; H Feistel; F Wolf; W Jäger
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

8.  Reduced antibody response to streptavidin through site-directed mutagenesis.

Authors:  D L Meyer; J Schultz; Y Lin; A Henry; J Sanderson; J M Jackson; S Goshorn; A R Rees; S S Graves
Journal:  Protein Sci       Date:  2001-03       Impact factor: 6.725

9.  In vitro and in vivo properties of an anti-CD5-momordin immunotoxin on normal and neoplastic T lymphocytes.

Authors:  G Porro; A Bolognesi; P Caretto; G Gromo; P Lento; G Mistza; T Sciumbata; F Stirpe; D Modena
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

10.  A critical comparison of three internalization assays applied to the evaluation of a given mAb as a toxin-carrier candidate.

Authors:  P Casalini; M Caldera; S Canevari; S Ménard; D Mezzanzanica; E Tosi; M Gadina; M I Colnaghi
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.